APA (7th ed.) Citation

Y, T., A, T., M, O., D, H., SI, I., K, N., . . . Y, K. (2024). Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status. BMC pulmonary medicine, 24(1), 407. https://doi.org/10.1186/s12890-024-03212-5

Chicago Style (17th ed.) Citation

Y, Taniguchi, et al. "Baseline Genetic Abnormalities and Effectiveness of Osimertinib Treatment in Patients with Chemotherapy-naïve EGFR-mutated NSCLC Based on Performance Status." BMC Pulmonary Medicine 24, no. 1 (2024): 407. https://doi.org/10.1186/s12890-024-03212-5.

MLA (9th ed.) Citation

Y, Taniguchi, et al. "Baseline Genetic Abnormalities and Effectiveness of Osimertinib Treatment in Patients with Chemotherapy-naïve EGFR-mutated NSCLC Based on Performance Status." BMC Pulmonary Medicine, vol. 24, no. 1, 2024, p. 407, https://doi.org/10.1186/s12890-024-03212-5.